Apellis Pharmaceuticals, Inc.

Neurocrine Updates On Crenessity Launch Neurocrine Biosciences announced encouraging early sales for its new commercial product, Crenessity (crinecerfont), in its first full quarter of launch. Crene

The European Medicines Agency hit a 15-year high for positive drug recommendations in 2024, with 114 new medicines gaining a positive opinion for regulatory approval across the EU from its human medic

Outlook Therapeutics is remaining hopeful that the US Food and Drug Administration will approve ONS-5010 for wet age-related macular degeneration (AMD) despite the Phase III NORSE EIGHT study not meet

Outlook Therapeutics is remaining hopeful that the US Food and Drug Administration will approve its ONS-5010 bevacizumab candidate for wet age-related macular degeneration (AMD) despite the Phase III